Quantitative analysis for Attovia Therapeutics Inc. Common Stock (ATTO) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Buy (83.0) (grade A). 30 signals analyzed (24 differentiated alt-data).
ATTO stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-08-05 | $22.79 | $20.21 | $21.90 |
| 2026-08-10 | $20.17 | $18.50 | $19.84 |
| 2026-08-13 | $19.36 | $17.97 | $19.18 |
| 2026-08-18 | $23.75 | $20.96 | $23.24 |
| 2026-08-21 | $21.01 | $19.70 | $20.80 |
| 2026-08-26 | $20.35 | $18.85 | $19.55 |
| 2026-08-31 | $21.81 | $19.87 | $21.40 |
| 2026-09-03 | $26.07 | $23.46 | $24.20 |
| 2026-09-09 | $26.33 | $22.33 | $22.86 |
| 2026-09-14 | $25.30 | $22.28 | $24.52 |
| 2026-09-17 | $24.39 | $22.24 | $22.73 |
How Attovia Therapeutics Inc. Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AZN | AstraZeneca PLC | $290.7B | — |
| NVS | Novartis AG | $287.1B | — |
| NVO | Novo Nordisk A/S | $200.3B | — |
| SNY | Sanofi | $107.6B | — |
View all Health Care stocks by valuation and signals →
Attovia Therapeutics Inc. Common Stock (ATTO) scores Strong Buy (83.0), and the composite conceals a 85-point disagreement between its dimensions. It is strongest on technicals at 100 and ML forecast at 86, and weakest on competitive moat at 27 and analyst consensus at 15. A stock can carry technicals that high while analyst consensus sits at 15; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| technicals | 100 |
| ML forecast | 86 |
| competitive moat | 27 |
| analyst consensus | 15 |
StoQuant analyzes 30 signals (24 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Attovia Therapeutics Inc. Common Stock (ATTO): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ATTO"><img src="https://stoquant.com/badge/ATTO.svg" alt="Attovia Therapeutics Inc. Common Stock (ATTO) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.